Patents Represented by Attorney Miller, White, Zelano & Branigan, P.C.
  • Patent number: 8323800
    Abstract: The present invention relates to a method of bonding a gold surface to a second surface which comprises heating a hybrid organic-inorganic melting gel >50° C., applying the melting gel to either the gold surface or the second surface. The melting gel is heated to above 130° C. until the melting gel has cured sufficiently to bond the surfaces together. The invention also relates to a combination of a gold surface and a second surface that is bonded together with a hybrid organic-inorganic melting gel. In another aspect of the invention the hybrid organic-inorganic melting gel is heated to a workable viscosity and cast into a film, sheet, block or lens. The cast gel is cured or partially cured and then applied between the gold surface and the second surface. Additional uncured melting gel may be applied. The construct is heated to above 130° C. until the melting gel has cured sufficient to bond the surfaces together.
    Type: Grant
    Filed: June 9, 2009
    Date of Patent: December 4, 2012
    Assignee: Schott Corporation
    Inventors: Daniel Haines, David Yuhas, Eric Urruti
  • Patent number: 8299018
    Abstract: Disclosed are a fusion protein comprising enzyme N-acetylgalactosamine-6-sulfate sulfatase and a short peptide consisting of 4-15 acidic amino acids attached to the enzyme on its N-terminal side, a pharmaceutical composition containing the fusion protein, and a method for treatment of type A Morquio disease using the fusion protein. Compared with the native enzyme protein, the fusion protein exhibits higher transferability to bone tissues and improved, higher stability in the blood.
    Type: Grant
    Filed: December 12, 2008
    Date of Patent: October 30, 2012
    Assignees: Saint Louis University, Kanazawa University, JCR Pharmaceuticals Co., Ltd.
    Inventors: Shunji Tomatsu, Ken'ichi Miyamoto, Masamichi Yamada, Yasuhiro Tosaka, Mana Yamada
  • Patent number: 8207525
    Abstract: An organic thin film transistor including a substrate having thereon at least three terminals of a gate electrode, a source electrode and a drain electrode, an insulator layer and an organic semiconductor layer, with a current between a source and a drain being controlled upon application of a voltage to the gate electrode, wherein the organic semiconductor layer includes a specified organic compound having an aromatic heterocyclic group in the center thereof; and an organic thin film light emitting transistor utilizing an organic thin film transistor, wherein the organic thin film transistor is one in which light emission is obtained utilizing a current flowing between the source and the drain, and the light emission is controlled upon application of a voltage to the gate electrode, and is made high with respect to the response speed and has a large ON/OFF ratio, are provided.
    Type: Grant
    Filed: November 28, 2007
    Date of Patent: June 26, 2012
    Assignee: Idemitsu Kosan Co., Ltd.
    Inventors: Masatoshi Saito, Yuki Nakano, Hiroaki Nakamura
  • Patent number: 7879314
    Abstract: The present invention concerns the use of indocarbocyanine dyes, in particular indotricarbocyanine dyes for the diagnosis of inflammatory diseases, in particular rheumatoid arthritis, methods of diagnosing inflammatory diseases and an apparatus useful to carry out the method of diagnosing.
    Type: Grant
    Filed: June 28, 2006
    Date of Patent: February 1, 2011
    Assignee: Bayer Schering Pharma AG
    Inventors: Kai Licha, Michael Schirner, Axel Vater, Sonja Vollmer
  • Patent number: 7816376
    Abstract: The invention relates to compounds of the formula (I) and pharmaceutically usable derivatives, salts, solvates and stereoisomers and mixtures thereof, in which X, Y, Z, R1, R3, R4, R8, p, k, E, G, Z and Q are as defined in claim 1, which are employed as excitatory amino acid antagonists for combating neurodegenerative diseases, including cerebrovascular diseases, epilepsy, schizophrenia, Alzheimer's, Parkinson's or Huntington's disease, cerebral ischaemia, infarction or psychoses.
    Type: Grant
    Filed: March 5, 2003
    Date of Patent: October 19, 2010
    Assignee: Merck Patent GmbH
    Inventors: Oliver Schadt, Joachim Leibrock, Helmut Pruecher, Christoph Seyfried
  • Patent number: 7767455
    Abstract: The present invention relates to reporter systems for RNA export, methods for searching for molecules which influence RNA export, and a method, based on these methods, for detecting a viral infection.
    Type: Grant
    Filed: October 30, 2001
    Date of Patent: August 3, 2010
    Assignee: Geneart GmbH
    Inventors: Ralf Wagner, Marcus Graf
  • Patent number: 7718050
    Abstract: The invention relates to a process for FCC pretreatment by mild hydrocracking of a hydrocarbon feedstock that comprises a vacuum distillate fraction or a deasphalted oil or else a mixture of these two fractions, said primary feedstock, to produce gas oil and an effluent having an initial boiling point of more than 320° C., said effluent (FCC feedstock) then being subjected to a catalytic cracking, process in which at least 85% by weight of said primary feedstock ends above 375° C. and at least 95% by weight of said primary feedstock ends below 650° C., whereby the mild hydrocracking is performed under an absolute pressure of 2 to 12 MPa and at a temperature of between 300 and 500° C., characterized in that the hydrocarbon feedstock also comprises a lighter hydrocarbon fraction, a so-called secondary feedstock, of which at least 50% by weight ends below 375° C. and at least 80% ends above 200° C.
    Type: Grant
    Filed: June 9, 2006
    Date of Patent: May 18, 2010
    Assignee: Institut Francais du Petrole
    Inventors: Christophe Gueret, Thierry Chapus, Damien Hudebine
  • Patent number: 7700621
    Abstract: This invention describes the new 6-alkenyl- and 6-alkinyl-epothilone derivatives of general formula (I) in which R1a, R1b, R2a, R3a, R3b, R4, R5, R6, R7, A, Y, D, E, G, Y and Z have the meanings that are indicated in the description. The new compounds interact with tubulin by stabilizing microtubuli that are formed. They are able to influence the cell-splitting in a phase-specific manner and thus find use in treating diseases or conditions associated with the need for cell growth, division and/or proliferation. Thus the compounds are suitable for treating malignant tumors, for example, ovarian, stomach, colon, adeno-, breast, lung, head and neck carcinomas, malignant melanoma, acute lymphocytic and myelocytic leukemia. In addition, they are suitable for anti-angiogenesis therapy as well as for treatment of chronic inflammatory diseases (such as psoriasis, arthritis). Methods of use and preparation of the compounds are also described.
    Type: Grant
    Filed: August 31, 2005
    Date of Patent: April 20, 2010
    Assignee: Bayer Schering Pharma Aktiengesellschaft
    Inventors: Ulrich Klar, Wolfgang Schwede, Werner Skuballa, Bernd Buchmann, Jens Hoffmann, Rosemarie Lichtner
  • Patent number: 7615565
    Abstract: VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridinamides, their production and use as pharmaceutical agents for treating diseases that are triggered by persistent angiogenesis, as well as intermediate products for the production of the compounds are described. The compounds according to the invention can be used as or in the case of tumor or metastasis growth, psoriasis, Kaposi's sarcoma, restenosis, such as, e.g.
    Type: Grant
    Filed: September 22, 2006
    Date of Patent: November 10, 2009
    Assignee: Bayer Schering Pharma Aktiengesellschaft
    Inventors: Andreas Huth, Ludwig Zorn, Martin Kruger, Stuat Ince, Karl-Heinz Thierauch, Andreas Menrad, Martin Haberey, Holger Hess-Stumpp
  • Patent number: 7550491
    Abstract: The present invention relates to salts comprising bis(trifluoromethyl)imide anions and saturated, partially or fully unsaturated, heterocyclic cations, to a process for the preparation thereof, and to the use thereof as ionic liquids.
    Type: Grant
    Filed: November 17, 2003
    Date of Patent: June 23, 2009
    Assignee: Merck Patent GmbH
    Inventors: Nikolai Ignatyev, Urs Welz-Biermann, Michale Schmidt, Helge Willner, Andriy Kucheryna
  • Patent number: 7488833
    Abstract: A process for the enantioselective preparation of amino alcohols of formula I by enantioselective hydrogenation of amino ketones of the formula II in the presence of a non-racemic catalyst. The catalyst is a transition-metal complex in which the transition metal is complexed to a chiral diphosphine ligand.
    Type: Grant
    Filed: August 1, 2003
    Date of Patent: February 10, 2009
    Assignee: Merck Patent GmbH
    Inventors: Joachim Kralik, Kai Fabian, Christoph Mürmann, Norbert Schweickert
  • Patent number: 7462718
    Abstract: A process for the production of high-purity rac-1-{4-[2-hydroxy-3-(5-quinolyloxy)propyl]-piperazin-1-yl}-2,2-diphenylethan-1-one fumarate as well as rac-1-{4-[2-hydroxy-3-(5-quinolyloxy)propyl]piperazin-1-yl}-2,2-diphenylethan-1-one fumarate at a purity of at least 98.55% is described.
    Type: Grant
    Filed: May 6, 2004
    Date of Patent: December 9, 2008
    Assignee: Schering AG
    Inventors: Hilmar Weinmann, Matthias Schneider, Michael Gottfried
  • Patent number: 7442814
    Abstract: The present invention relates to the compounds of general formula (I) wherein R, R1, R2 are as defined in claim 1. Compounds of formula (I) are particularly useful for preparing 3,3-dimethyl-5-formyl-2,3-dihydrobenzoxepines derivatives.
    Type: Grant
    Filed: April 5, 2005
    Date of Patent: October 28, 2008
    Assignee: Merck Patent GmbH
    Inventors: Twana Saleh, Bernard Boudet
  • Patent number: 7425356
    Abstract: The invention relates to chiral compounds of formula I wherein X1, X2, X1, X2, x1, x2, y1, y2, B, C, U1, U2, V1, V2, W1 and W2 have the meaning given in claim 1, to liquid crystal mixtures comprising at least one chiral compound of formula I, to chiral linear or crosslinked liquid crystal polymers obtainable by polymerizing a polymerizable mixture comprising at least one chiral compound of formula I, to the use of chiral compound of formula I and mixtures and polymers obtained thereof in liquid crystal displays, active and passive optical elements, adhesives, synthetic resins with anisotropic mechanical properties, cosmetic and pharmaceutical compositions, diagnostics, liquid crystal pigments, for decorative and security applications, nonlinear optics, optical information storage or as chiral dopants, and to a liquid crystal display comprising a mixture comprising at least one chiral compound of formula I.
    Type: Grant
    Filed: May 24, 2007
    Date of Patent: September 16, 2008
    Assignee: Merck Patent GmbH
    Inventors: Andreas Taugerbeck, Peer Kirsch, Detlef Pauluth, Joachim Krause, Juliane Suermann, Michael Heckmeier
  • Patent number: 7390538
    Abstract: The present invention relates to a liquid-crystalline medium based on a mixture of polar compounds of positive or negative dielectric anisotropy which is characterised in that it comprises one or more compounds of the general formula I in which R1 and R2 are each, independently of one another, identically or differently, H, an alkyl radical having from 1 to 12 carbon atoms which is unsubstituted, monosubstituted by CN or CF3 or at least monosubstituted by halogen, where, in addition, one or more CH2 groups in these radicals may each, independently of one another, be replaced by —O—, —S—, —CH?CH—, —C?C—, —CO—, —CO—O, —O—CO— or —O—CO—O— in such a way that 0 atoms are not linked directly to one another, to the use thereof for electro-optical purposes, and to electro-optical display devices which contain this medium.
    Type: Grant
    Filed: June 23, 2004
    Date of Patent: June 24, 2008
    Assignee: Merck Patent GmbH
    Inventors: Atsutaka Manabe, Erdal Durmaz, Eike Poetsch, Volker Reiffenrath, Michael Heckmeier
  • Patent number: 7371756
    Abstract: 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine or a physiologically acceptable salt thereof, for the treatment of sub-type anxiety disorders chosen from the sub-types: panic disorder with or without agoraphobia, agoraphobia, obsessive-compulsive spectrum disorders, social phobia, posttraumatic stress disorder, acute stress indication or generalized anxiety disorder, bipolar disorders, mania, dementia, substance-related disorders, sexual dysfunctions, eating disorders, obesity, anorexia, and fibromyalgia. A preferred salt is 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine hydrochloride.
    Type: Grant
    Filed: November 23, 2004
    Date of Patent: May 13, 2008
    Assignee: Merck Patent GmbH
    Inventors: Gerd Bartoszyk, Christoph Seyfried, Christoph Von Amsterdam, Henning Boettcher, Ewen Sedman
  • Patent number: 7344761
    Abstract: The invention relates to liquid-crystalline compounds of the formula (I), where R11, X11, L11, Y and W are as defined in claim 1, and to the use thereof in liquid-crystalline media, to liquid-crystalline media comprising at least one compound of the formula (I) and to electro-optical displays containing a liquid-crystalline medium of this type
    Type: Grant
    Filed: May 24, 2004
    Date of Patent: March 18, 2008
    Assignee: Merck Patent Gesellaschaft mit Beschrankter Haftung
    Inventors: Peer Kirsch, Eike Poetsch, Alexander Hahn, Werner Binder, Volker Meyer, Michael Heckmeier, Georg Luessem, Melanie Klasen-Memmer
  • Patent number: 7338776
    Abstract: A purified novel enzyme protein, UGPPase, which naturally occurs in animal cells, its productions of recombinant technology, an antibody to the enzyme protein, a method of carrying out ELISA for measurement of the amount of UGPPase in an analyte and a method for determination of UDPG in a sample. The one-way enzyme protein catalyses hydrolysis of UDP-glucose, the precursor molecule of glycogen, into glucose-1-phosphate (G1P) and uridine 5?-monophosphate (UMP).
    Type: Grant
    Filed: March 17, 2003
    Date of Patent: March 4, 2008
    Assignees: JCR Pharmaceuticals Co., Ltd., Universidad Publica De Navarra Campus Arrosadia
    Inventors: Javier Pozueta Romero, Edurne Baroja Fernandez, Francisco Jose Munoz, Imbak Shu, Ryuji Yamamoto
  • Patent number: 7325594
    Abstract: A heat exchanger having at least one heat exchanger block (1) and an insulating vessel which surrounds the heat exchanger, is provided with plates and joints for securing the heat exchanger block (1) suspended in the insulation vessel. In addition, the heat exchanger block (1) is arranged movably in the insulation vessel.
    Type: Grant
    Filed: March 6, 2002
    Date of Patent: February 5, 2008
    Assignee: Linde Aktiengesellschaft
    Inventors: Stefan Wilhelm, Wolfgang Bader
  • Patent number: 7319154
    Abstract: This invention relates to processes for the production of 3-oxo-pregnane-21,17-carbolactones of formula II as well as 3-oxo-pregn-4-ene-21,17-carbolactones of formula III by the metal-free oxidation of 17-(3-hydroxypropyl)-3,17-dihydroxyandrostanes of formula I In addition, the invention relates to the dichloromethane hemisolvate of 6B,7B;15?,16?-diethylene-3-oxo-17?-pregnan-5?-ol-21,17-carbolactone (IV) as such.
    Type: Grant
    Filed: July 21, 2005
    Date of Patent: January 15, 2008
    Assignee: Bayer Schering Pharma AG
    Inventors: Carsten Seilz, Hartmut Seba